Vericel Corporation
Financials
Valuation Metrics
Vericel Corporation's Market Cap is $2.35B. At end of 2025 it was $1.82B. Ranked #1948 of 3,112 in US market (top 63%), #731 of 1,445 on NASDAQ (top 51%), #121 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 45%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.35B | US#1,948/3,112 Sec#121/269 |
| Revenue | $306M | US#2,543/3,112 Sec#95/269 |
| Net Income | $24M | US#2,035/3,112 Sec#67/269 |
| Total Assets | $503M | US#2,742/3,112 Sec#158/269 |
| Net Assets | $370M | US#2,448/3,112 Sec#145/269 |
| Employees | 398 | US#1,382/3,112 Sec#50/269 |
| Value | ||
| P/E | 97.09x | US#2,045/3,112 Sec#64/269 |
| P/B | 6.36x | US#2,351/3,112 Sec#164/269 |
| PEG | 1.63x | US#992/3,112 Sec#32/269 |
| P/S | 7.68x | US#2,551/3,112 Sec#108/269 |
| EV/EBITDA | 60.30x | US#2,384/3,112 Sec#82/269 |
| FCF Yield | 2.11% | US#1,933/3,112 Sec#69/269 |
| Profitability | ||
| ROE | 6.55% | US#1,707/3,112 Sec#62/269 |
| ROA | 4.82% | US#1,031/3,112 Sec#52/269 |
| Op. Margin | 5.95% | US#1,975/3,112 Sec#74/269 |
| Revenue Growth | 22.48% | US#667/3,112 Sec#76/269 |
| Earnings Growth | 59.41% | US#508/3,112 Sec#25/269 |
| Financial Health | ||
| Debt Ratio | 35.89% | US#405/3,112 Sec#115/269 |
| Total Debt | $93M | US#2,410/3,112 Sec#121/269 |
| FCF | $50M | US#1,933/3,112 Sec#69/269 |
| Cash | $125M | US#2,065/3,112 Sec#162/269 |
| Current Ratio | 5.04x | US#468/3,112 Sec#143/269 |
| Net Debt/EBITDA | -0.85x | US#340/3,112 Sec#23/269 |
| Performance | ||
| 1Y Return | 29.25% | US#1,395/3,112 Sec#160/269 |
| 1M Return | -1.98% | US#1,914/3,112 Sec#99/269 |
| From 52W High | -6.63% | US#724/3,112 Sec#29/269 |
| 1Y MDD | -35.80% | US#1,734/3,112 Sec#117/269 |
| Trading | ||
| Volume | 485,442 shares | US#2,096/3,112 Sec#205/269 |
| Trading Value | $23M | US#1,892/3,112 Sec#135/269 |
| Per Share | ||
| EPS | $0.33 | US#1,921/3,112 Sec#66/269 |
| BPS | $7.01 | US#2,045/3,112 Sec#103/269 |
Company Info
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.